Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZomedicaZOMDF +1.04% EV-to-EBIT is -1.61 as of Jul. 23, 2026. The stock has 3 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Zomedica ranks worse than 215053.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zomedica's Enterprise Value for the quarter that ended in Mar. 2026 was $71.51 Mil.
Zomedica's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zomedica EV-to-EBIT Related Terms
Zomedica EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zomedica's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Zomedica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zomedica EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zomedica's EV-to-EBIT falls into.
Zomedica's current Enterprise Value is $39.65 Mil.
Zomedica's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zomedica (ZOMDF) has a EV-to-EBIT of -1.61 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zomedica and its competitors. According to the industry distribution chart, Zomedica ranks #999999 out of 465 companies in the Medical Devices & Instruments industry.
Is Zomedica's EV-to-EBIT too high?
Zomedica's current EV-to-EBIT is -1.61. Based on the distribution chart, Zomedica ranks #999999 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Zomedica's EV-to-EBIT compare to STIM and OM?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #999999 out of 465 companies for EV-to-EBIT. This places Zomedica in the lower half of its industry. The industry median EV-to-EBIT is 18.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.24, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zomedica and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current EV-to-EBIT is -1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.09 — trading 54.3% below its estimated fair value. The current EV-to-EBIT is -1.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zomedica (ZOMDF), the current EV-to-EBIT is -1.61 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZOMDF has been successfully added to your 
